ADS Biosystems

San Diego, United States· Est. 2019

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Total funding raised: $2.5M

Overview

ADS Biosystems Inc. is a specialized contract research organization focused on providing preclinical testing services, particularly in the niche area of hearing research using animal cochlear organ cultures. The company has established long-term collaborations with top-tier pharmaceutical companies and academic institutions, including BMS/Celgene, JNJ, Roche/Genentech, Sanofi Europe, UCSD, and UC Davis. Their expertise in custom cell-based assays and organ culture models positions them as a valuable partner for drug discovery programs targeting auditory conditions and other therapeutic areas requiring sophisticated biological testing.

Hearing DisordersOtologyNeuroscience

Technology Platform

Specialized animal cochlear organ cultures for hearing studies and custom cell-based assay development for preclinical drug testing.

Funding History

Total raised:$2.5M

Seed$2.5MUndisclosedJun 15, 2021

Opportunities

Growing pharmaceutical investment in hearing loss treatments creates increased demand for specialized preclinical models like cochlear organ cultures.

The company can expand services into related neurological organ culture models and leverage the aging population trend driving research in age-related hearing disorders.

Partnerships with hearing aid or medical device companies represent additional growth avenues beyond traditional pharmaceutical clients.

Risk Factors

Client concentration risk with reliance on a few major pharmaceutical partners, technological obsolescence as alternative preclinical models emerge, and talent retention challenges in a competitive market for specialized scientists.

Economic downturns may lead pharmaceutical clients to reduce outsourcing budgets, impacting revenue stability.

Competitive Landscape

Faces competition from large full-service CROs (IQVIA, LabCorp), specialized preclinical providers (Charles River, Eurofins), and academic core facilities. Differentiation comes from specialized expertise in cochlear organ cultures, long-term pharmaceutical partnerships, and custom assay development flexibility. Maintaining this niche expertise against larger competitors with greater resources is an ongoing challenge.